SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-059527
Filing Date
2024-05-14
Accepted
2024-05-14 16:07:13
Documents
12
Period of Report
2024-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K antx-20240514.htm   iXBRL 8-K 39777
2 EX-99.1 antx-ex99_1.htm EX-99.1 91249
  Complete submission text file 0000950170-24-059527.txt   256869

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT antx-20240514.xsd EX-101.SCH 26028
15 EXTRACTED XBRL INSTANCE DOCUMENT antx-20240514_htm.xml XML 4911
Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

IRS No.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41331 | Film No.: 24944305
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)